Lantheus Holdings, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Lantheus Holdings, Inc. (LNTH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $86.14 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- Lantheus Holdings, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $86.14, a 23.07% increase from fiscal 2024.
- Lantheus Holdings, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $69.99, a 8.40% decline from fiscal 2023.
- Lantheus Holdings, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $76.41, a 42.69% increase from fiscal 2022.
- Lantheus Holdings, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $53.55.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|
| 2025-12-31 | $86.14 10-K · filed 2026-02-26 | ||
| 2024-12-31 | $69.99 10-K · filed 2025-02-26 | ||
| 2023-12-31 | $76.41 10-K · filed 2024-02-22 | ||
| 2022-12-31 | $53.55 10-K · filed 2023-02-23 | ||
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 | ||
| 2020-12-31 | $19.44 10-K · filed 2021-02-25 | ||
| 2019-12-31 | $0.00 10-K · filed 2020-02-25 | ||
| 2018-12-31 | $0.00 10-K · filed 2019-02-20 | ||
| 2017-12-31 | $0.00 10-K · filed 2018-02-26 | ||
| 2016-12-31 | $0.00 10-K · filed 2017-02-23 | ||
| 2015-12-31 | $12.11 10-K · filed 2016-03-02 | ||
| 2015-09-30 | $12.11 10-Q · filed 2015-11-04 | ||
| 2015-06-30 | $12.24 10-Q · filed 2015-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |